Qomolangma Acquisition Corp.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121390024058610 Filed on July 02, 2024

Income Statement

Concept	2024 Q3	2023 Q4	2023

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.220K	$9.220K
YoY Change	-95.39%	-95.39%
Cash & Equivalents	$9.222K
Short-Term Investments
Other Short-Term Assets	$69.78K	$69.78K
YoY Change	-70.93%	-70.93%
Inventory
Prepaid Expenses	$69.78K
Receivables
Other Receivables
Total Short-Term Assets	$79.00K	$79.00K
YoY Change	-81.71%	-81.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.299M	$9.299M
YoY Change	-82.77%	-82.77%
Other Assets
YoY Change
Total Long-Term Assets	$9.299M	$9.299M
YoY Change	-82.77%	-82.77%
TOTAL ASSETS
Total Short-Term Assets	$79.00K	$79.00K
Total Long-Term Assets	$9.299M	$9.299M
Total Assets	$9.378M	$9.378M
YoY Change	-82.76%	-82.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$829.9K	$1.003M
YoY Change	566.08%	489.84%
Deferred Revenue
YoY Change
Short-Term Debt	$937.3K	$937.3K
YoY Change	485.78%	485.78%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.909M	$2.909M
YoY Change	683.8%	686.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.109M	$2.109M
YoY Change	-0.04%	-0.04%
Total Long-Term Liabilities	$2.109M	$2.109M
YoY Change	-0.04%	-0.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.909M	$2.909M
Total Long-Term Liabilities	$2.109M	$2.109M
Total Liabilities	$5.034M	$5.034M
YoY Change	100.04%	99.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.483M
YoY Change	-3524.62%
Common Stock	$166.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.483M	$4.344M
YoY Change
Total Liabilities & Shareholders Equity	$9.378M	$9.378M
YoY Change	-82.76%	-82.76%

Cashflow Statement

Concept	2024 Q3	2023 Q4	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41518
CY2023	dei	Entity Registrant Name EntityRegistrantName	QOMOLANGMA Acquisition Corp.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3733656
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1178 Broadway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2023	dei	City Area Code CityAreaCode	(512)
CY2023	dei	Local Phone Number LocalPhoneNumber	340-7800
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	32782008	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2500480	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Costa Mesa, CA
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9222	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	196510	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	69781	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	235476	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	79003	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	431986	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	9299336	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	53958681	usd
CY2023Q4	us-gaap	Assets Assets	9378339	usd
CY2022Q4	us-gaap	Assets Assets	54390667	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	829931	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	96212	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	148387	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	28387	usd
CY2023Q4	qomo	Franchise Tax Payable FranchiseTaxPayable	24400	usd
CY2022Q4	qomo	Franchise Tax Payable FranchiseTaxPayable	45428	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	434300	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	46115	usd
CY2023Q4	qomo	Exercise Tax Liabilies ExerciseTaxLiabilies	469218	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2909214	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	371167	usd
CY2023Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	15684	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	36164	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2109200	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2109200	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5034098	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2516531	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	16000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	16000000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	837857	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	837857	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5273000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5273000	shares
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.54
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	8.88
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8827454	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	46828833	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	166	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	166	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4914221	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4483379	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	130916	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4483213	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5045303	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9378339	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54390667	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1624171	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	174673	usd
CY2023	qomo	Franchise Tax Expense FranchiseTaxExpense	24400	usd
CY2022	qomo	Franchise Tax Expense FranchiseTaxExpense	45928	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1648571	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-220601	usd
CY2023	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	1925395	usd
CY2022	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	437731	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	276824	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	217130	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	415729	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	82279	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138905	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	134851	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5045303	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	8920393	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-469218	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138905	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4483213	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21065	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	52730000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2693725	usd
CY2022	qomo	Stock Issued During Period Value Issuance Of Representative Shares StockIssuedDuringPeriodValueIssuanceOfRepresentativeShares	673500	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3031975	usd
CY2022	qomo	Stock Issued During Period Value Offering Costs StockIssuedDuringPeriodValueOfferingCosts	-1347030	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	43419193	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3409640	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	134851	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5045303	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138905	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	134851	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1925395	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	437731	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-20480	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	36164	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-165695	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	235476	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	733720	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	59599	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	120000	usd
CY2023	qomo	Increase Decrease In Franchise Tax Payable IncreaseDecreaseInFranchiseTaxPayable	-21028	usd
CY2022	qomo	Increase Decrease In Franchise Tax Payable IncreaseDecreaseInFranchiseTaxPayable	45428	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	388185	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	46115	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-698208	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-351050	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	53520950	usd
CY2023	qomo	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	-63129	usd
CY2023	qomo	Cash From Trust Account To Pay Franchise Tax CashFromTrustAccountToPayFranchiseTax	96453	usd
CY2023	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	46921772	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	46955096	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53520950	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	52730000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2693725	usd
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	65726	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	411870	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	153525	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-200000	usd
CY2022	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	922775	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	540530	usd
CY2023	qomo	Payment Of Public Stockholder Redemptions PaymentOfPublicStockholderRedemptions	46921772	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-46444176	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53913945	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-187288	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	41945	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196510	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154565	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9222	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196510	usd
CY2022	qomo	Redeemed Common Stock Payable To Public Stockholders RedeemedCommonStockPayableToPublicStockholders	43419193	usd
CY2022	qomo	Deferred Offering Costs In Accrued Offering Costs DeferredOfferingCostsInAccruedOfferingCosts	2109200	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	8920393	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	3409640	usd
CY2023	qomo	Exercise Tax Liability ExerciseTaxLiability	469218	usd
CY2023	qomo	Extension Fee Deposited Into Trust Account By The Sponsor ExtensionFeeDepositedIntoTrustAccountByTheSponsor	370357	usd
CY2023	qomo	Franchise And Income Tax Paid FranchiseAndIncomeTaxPaid	48024	usd
CY2023Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	4222030	usd
CY2023	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	875000	usd
CY2023	qomo	Deferred Underwriting Fees DeferredUnderwritingFees	2000000	usd
CY2023	qomo	Offering Cost OfferingCost	1347030	usd
CY2023	qomo	Maturity Days MaturityDays	P185D
CY2023	qomo	Trust Account Description TrustAccountDescription	Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test.
CY2023	qomo	Financing Receivable Non Accrual To Outstanding Percent FinancingReceivableNonAccrualToOutstandingPercent	0.50	pure
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.15
CY2023	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	5000001	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2023	qomo	Deposit Into Trust Account DepositIntoTrustAccount	174009	usd
CY2023	us-gaap	Investment Company Issuance Of Shares Per Share InvestmentCompanyIssuanceOfSharesPerShare	0.033
CY2023Q4	qomo	Aggregate Shares AggregateShares	1233054	shares
CY2023	qomo	Redemption Value RedemptionValue	13082703	usd
CY2023Q4	qomo	Common Stock Other Shares CommonStockOtherShares	3575635	shares
CY2023Q4	qomo	Percentage Of Common Stock Other Shares PercentageOfCommonStockOtherShares	0.8118	pure
CY2023Q4	us-gaap	Investment Company Issuance Of Shares Per Share InvestmentCompanyIssuanceOfSharesPerShare	0.033
CY2023Q4	qomo	Deposit Into Trust Account DepositIntoTrustAccount	20000	usd
CY2023Q4	us-gaap	Deposits Deposits	63129	usd
CY2023Q4	qomo	Extension Fee ExtensionFee	38043	usd
CY2023Q4	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	10.15
CY2023Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	10.15
CY2023Q4	us-gaap	Cash Available For Distributions CashAvailableForDistributions	9222	usd
CY2023	qomo	Working Capital WorkingCapital	2830211	usd
CY2023Q1	us-gaap	Policy Loans Receivable PolicyLoansReceivable	200000	usd
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	240000	usd
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	150000	usd
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	47227	usd
CY2023Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	145000	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	38043	usd
CY2022Q3	qomo	Effective Income Tax Rate Reconciliation At Federal Excise Tax Percentage EffectiveIncomeTaxRateReconciliationAtFederalExciseTaxPercentage	0.01	pure
CY2022Q3	qomo	Excise Tax Percentage ExciseTaxPercentage	0.01	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	9222	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	196510	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	4222030	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138905	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	134851	usd
CY2023	qomo	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	-8920393	usd
CY2022	qomo	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	-3409640	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-9059298	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-3274790	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of December 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2023	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Redemption Value RedeemableNoncontrollingInterestEquityCommonRedemptionValue	8936913	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Redemption Value RedeemableNoncontrollingInterestEquityCommonRedemptionValue	3409640	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	52730000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3532910	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1845550	usd
CY2022	qomo	Allocation Of Offering Costs Related To Redeemable Shares AllocationOfOfferingCostsRelatedToRedeemableShares	-3932347	usd
CY2022	qomo	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	-3409640	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	46828833	usd
CY2023	qomo	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	-8920393	usd
CY2023	qomo	Redeemed Common Stock Payable To Public Stockholders1 RedeemedCommonStockPayableToPublicStockholders1	-46921772	usd
CY2023Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	8827454	usd
CY2022Q4	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	750000	shares
CY2023	qomo	Initial Public Offering Description InitialPublicOfferingDescription	Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”) and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
CY2023	qomo	Initial Public Offering Expiration InitialPublicOfferingExpiration	P5Y
CY2023	qomo	Public Shares Sold PublicSharesSold	5273000	shares
CY2023	qomo	Aggregate Purchase Price AggregatePurchasePrice	2605000	usd
CY2023	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	8873	shares
CY2023	qomo	Private Placement Description PrivatePlacementDescription	Each Private Unit consists of one share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
CY2022Q4	qomo	Shares Forfeited SharesForfeited	119250	shares
CY2022Q4	qomo	Subject To Forfeiture Shares SubjectToForfeitureShares	1318250	shares
CY2023	qomo	Founder Shares Percentage FounderSharesPercentage	0.50	pure
CY2021Q3	qomo	Aggregate Amount AggregateAmount	200000	usd
CY2022Q4	qomo	Repaid Outstanding Balance RepaidOutstandingBalance	200000	usd
CY2022Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	155025	usd
CY2023Q1	us-gaap	Policy Loans Receivable PolicyLoansReceivable	200000	usd
CY2023Q2	us-gaap	Policy Loans Receivable PolicyLoansReceivable	240000	usd
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	150000	usd
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	47227	usd
CY2023Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	145000	usd
CY2023	qomo	Outstanding Promissory Note OutstandingPromissoryNote	937252	usd
CY2022	qomo	Outstanding Promissory Note OutstandingPromissoryNote	155025	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1500000	usd
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	10
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	148387	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	28387	usd
CY2023	qomo	Additional Units To Underwriters AdditionalUnitsToUnderwriters	750000	shares
CY2022Q4	qomo	Purchase Units PurchaseUnits	273000	shares
CY2023	qomo	Deferred Underwriting Discount Percentage DeferredUnderwritingDiscountPercentage	0.0175	pure
CY2023	qomo	Deferred Fee Percentage DeferredFeePercentage	0.04	pure
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the common stock are entitled to one vote for each share
CY2021Q4	qomo	Percentage Of Issued And Outstanding Shares PercentageOfIssuedAndOutstandingShares	0.20	pure
CY2022Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	119250	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	837857	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5273000	shares
CY2023	qomo	Redeem Outstanding Warrants Description RedeemOutstandingWarrantsDescription	●in whole and not in part; ●at a price of $0.01 per warrant; ●upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period; ●if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the warrant holders.
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	9299336	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	53958681	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	377757	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	35855	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	15684	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	36164	usd
CY2023Q4	qomo	Deferred Tax Assets Liabilitie Net DeferredTaxAssetsLiabilitieNet	-362073	usd
CY2022Q4	qomo	Deferred Tax Assets Liabilitie Net DeferredTaxAssetsLiabilitieNet	309	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	377757	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35855	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15684	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	36164	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	436209	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	46115	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-361555	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	309	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	341075	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35855	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	415729	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	82279	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2023	qomo	Effective Income Tax Rate Tax Penaltiesin Dollars EffectiveIncomeTaxRateTaxPenaltiesinDollars	0.06	pure
CY2022	qomo	Effective Income Tax Rate Tax Penaltiesin Dollars EffectiveIncomeTaxRateTaxPenaltiesinDollars	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	1.232	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.169	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	1.502	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.379	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	341075	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35855	usd
CY2022Q4	qomo	Exercise Tax Liabilies ExerciseTaxLiabilies		usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock		usd
CY2022	qomo	Stock Issued During Period Value Forfeiture Of Founder Shares StockIssuedDuringPeriodValueForfeitureOfFounderShares		usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022	qomo	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount		usd
CY2022	qomo	Cash From Trust Account To Pay Franchise Tax CashFromTrustAccountToPayFranchiseTax		usd
CY2022	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty		usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2023	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	qomo	Payment Of Public Stockholder Redemptions PaymentOfPublicStockholderRedemptions		usd
CY2023	qomo	Redeemed Common Stock Payable To Public Stockholders RedeemedCommonStockPayableToPublicStockholders		usd
CY2023	qomo	Deferred Offering Costs In Accrued Offering Costs DeferredOfferingCostsInAccruedOfferingCosts		usd
CY2022	qomo	Exercise Tax Liability ExerciseTaxLiability		usd
CY2022	qomo	Extension Fee Deposited Into Trust Account By The Sponsor ExtensionFeeDepositedIntoTrustAccountByTheSponsor		usd
CY2022	qomo	Franchise And Income Tax Paid FranchiseAndIncomeTaxPaid		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001894210

Files In Submission

Name	View Source	Status
0001213900-24-058610-index-headers.html	Edgar Link	pending
0001213900-24-058610-index.html	Edgar Link	pending
0001213900-24-058610.txt	Edgar Link	pending
0001213900-24-058610-xbrl.zip	Edgar Link	pending
ea0207028-10k_qomolang.htm	Edgar Link	pending
ea020702801ex31-1_qomolang.htm	Edgar Link	pending
ea0207028-10k_qomolang_htm.xml	Edgar Link	completed
ea020702801ex31-2_qomolang.htm	Edgar Link	pending
ea020702801ex32-1_qomolang.htm	Edgar Link	pending
ea020702801ex32-2_qomolang.htm	Edgar Link	pending
ea020702801ex4-7_qomolang.htm	Edgar Link	pending
ea020702801ex97-1_qomolang.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qomo-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
qomo-20231231_cal.xml	Edgar Link	unprocessable
qomo-20231231_pre.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qomo-20231231_def.xml	Edgar Link	unprocessable
qomo-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Qomolangma Acquisition Corp.

2024 Q3 Form 10-K Financial Statement

#000121390024058610 Filed on July 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission